The Global CEO Initiative on Alzheimer’s Disease (CEOi)

  • We are excited to share that CEOi’s Blood-Based Biomarker Workgroup publication, “The Global CEO Initiative on Alzheimer’s Disease performance recommendations for blood-based biomarker tests,” is now released in Nature Reviews NeurologyClick here to read the publication.


The Global CEO Initiative on Alzheimer’s Disease (CEOi), founded in 2013, is an organization of private-sector leaders who have joined together to provide business leadership in the fight against Alzheimer’s. The CEOi believes that, during this era of aging populations, it will take visionary, coordinated, goal-oriented leadership of public and private leaders working together to solve our greatest challenges. It is convened by UsAgainstAlzheimer’s.


Our members and collaborators

Blood-Based Biomarker Workgroup

What is CEOi, and how do we address unmet needs in Alzheimer's care?

CEOi Executive Director Drew Holzapfel featured on Roche’s Alzheimer’s Disease Taxi discussing the biggest challenges to innovative treatments reaching patients and how cross-sector collaboration can address the most urgent, unmet needs in Alzheimer’s disease.

Lessons and Opportunities for the Alzheimer’s Community

Reflections on COVID-19

COVID-19 efforts provide powerful insights that can guide cross-sector responses to the dementia crisis. The Global CEO Initiative on Alzheimer’s Disease, Alzheimer’s Disease International and Hoffmann-La Roche wrote this report to stimulate discussion about how our world can apply these lessons to address Alzheimer’s disease: the growing pandemic.


A new podcast on stopping Alzheimer’s: A growing pandemic

Download CEOi’s new podcast series on how to end Alzheimer’s disease – a growing pandemic and one of the world’s most serious unmet health needs. As explained by the experts in this podcast, transparency, smart policy, and close collaboration can help stop the devastation Alzheimer’s unleashes on patients, families, health systems and entire economies.

In this episode, current and former regulatory officials take a page from the COVID-19 playbook, highlighting the vital need for transparent communication and cooperation across all stakeholders. The opportunity when done right?: The advancement of incremental innovations that can eventually transform a devastating disease into a manageable condition.